Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
OpGen, Inc. logo — company profile

OpGen, Inc.

Founded 2002 United States Rockville, United States 38 employees Post-IPO Equity Total: $118.63M Biotechnology, Health Care

General Information

Company Name OpGen, Inc.
Founded Year 2002
Location United States Rockville, United States
Employees 38
Industries Biotechnology, Health Care
Funding Stage Post-IPO Equity
Social

BounceWatch is an independent company data service, not affiliated with OpGen, Inc.. To contact OpGen, Inc., visit opgen.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does OpGen, Inc. compare?

A PDF of OpGen, Inc. and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting OpGen, Inc. soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About OpGen, Inc.

OpGen, Inc., a precision medicine company based in Rockville, Maryland, is a notable player in the Biotechnology and Health Care sectors. Founded in 2002, the company is at the forefront of developing molecular diagnostics aimed at combating infectious diseases and optimizing the treatment of drug-resistant infections.

Focusing on highly multiplexed syndromic molecular panels, OpGen aims to address the global challenge of antimicrobial resistance (AMR) and improve antibiotic stewardship. The innovative diagnostic solutions offered by the company have the potential to dramatically enhance patient care and curb the spread of multidrug-resistant microorganisms (MDROs).

Recently, OpGen secured a $3.00M Post-IPO Equity investment on 25 March 2024. This investment was led by David E Lazar, providing the company with fresh capital to further its mission. This investment highlights continued investor confidence in OpGen's cutting-edge molecular microbiology technology and its potential impact on global health.

Services & Products

Financial Technology Solutions
Investor Relations Services
Corporate Governance Management

Target Customers

Investors Board Members Corporate Businesses

Funding Rounds & Investors (15)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Equity $3.00M 1
David E Lazar
25 Mar 2024
Post IPO Equity $3.38M -
30 Sep 2022
Post IPO Equity $10.00M -
24 Nov 2020
Post IPO Equity $5.40M -
26 Mar 2019
Post IPO Equity $12.00M -
02 Feb 2018
Post IPO Equity $10.00M -
13 Jul 2017
Post IPO Equity $10.40M 2
Sabby Management, Merck Global Health Innovation Fund
20 May 2016
Post IPO Equity $6.00M 1
Merck Global Health Innovation Fund
14 Jul 2015
Debt Financing $1.24M -
23 Feb 2015
Series C $17.00M 6
Highland Capital Partners Versant Ventures 180 Degrees Capital
Highland Capital Partners, Versant Ventures +4
07 Mar 2012

View All 15 Funding Rounds

OpGen, Inc. Alternatives & Competitors

View All Alternatives
OpGen, Inc. vs
Ares Genetics GmbH
Ares Genetics GmbH

OpGen utilizes molecular microbiology and bioinformatics to develop diagnostic solutions aimed at im...

Seed
AI, Biotechnology
Compare OpGen, Inc. vs Ares Genetics GmbH
OpGen, Inc. vs
Selux Diagnostics, Inc
Selux Diagnostics, Inc United States

Precision diagnostics for infectious disease.

Series D
95 employees
Biotechnology, Health Care
Compare OpGen, Inc. vs Selux Diagnostics, Inc
OpGen, Inc. vs
Aidian
Aidian Finland

Aidian develops, manufactures and markets diagnostic tests and test solutions.

Venture round
205 employees
Biotechnology, Health Care
View all alternatives

FAQ About OpGen, Inc.

Mission We harness the power of molecular microbiology to develop diagnostic solutions that will optimize the treatment of life-threatening, drug resistant infections. We seek to dramatically transform patient care to guide antibiotic therapy selection and help improve antibiotic stewardship. Abou...
OpGen, Inc. was founded in 2002.
OpGen, Inc. is headquartered in Rockville, United States.
OpGen, Inc. operates in Biotechnology and Health Care. Its customers include Investors, Board Members and Corporate Businesses.
OpGen, Inc. has approximately 38 employees.
OpGen, Inc. has completed 15 funding rounds, raising a total of $118.63M. The latest funding stage is Post-IPO Equity.
OpGen, Inc. offers: Financial Technology Solutions, Investor Relations Services, Corporate Governance Management.
Top alternatives and competitors to OpGen, Inc. include Ares Genetics GmbH, Selux Diagnostics, Inc, Aidian. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
OpGen, Inc. and Ares Genetics GmbH are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for OpGen, Inc., https://bouncewatch.com/company/opgen-inc, updated 5 November 2025. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes